Action for Pulmonary Fibrosis > News > Treatment > IPF charities join forces to ask Minister for Health to work with NICE to make anti-fibrotic drugs available to more IPF patients

IPF charities join forces to ask Minister for Health to work with NICE to make anti-fibrotic drugs available to more IPF patients

Action for Pulmonary Fibrosis has joined forces with two other IPF charities, the British Lung Foundation and the Pulmonary Fibrosis Trust to ask the Health Minister Lord O’Shaughnessy to make anti-fibrotic drugs available to all patients who could benefit.

Currently, the two drugs available – Pirfenidone and Nintedanib – can only be prescribed for people whose lung function is between 80% and 50%. This despite the fact that one third of IPF patients are in the early stages of the disease. Such patients still have over 80% lung function and would benefit from the drug.

APF strongly recommends that NICE should change its guidance to make anti-fibrotic drugs available to all diagnosed IPF patients.
You can view a copy of the letter sent to Lord O’Shaughnessy here.

Click here to view the joint letter to the Minister

Sign up to receive our newsletter

Never miss our news—sign up to receive our quarterly newsletter and we'll keep you updated about any important announcements, new research and lots of fundraiser stories.